Clinical Trial Update: Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

View source ↗

Summary

This update notes that Janssen-Cilag's early-access program for telaprevir with peginterferon and ribavirin in chronic hepatitis C is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Telaprevir (telaprevir)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Hepatitis C | Status: NO_LONGER_AVAILABLE